RenovoRx RNXT 深 沪
等待开盘 11-14 09:30:00 美东时间
0.9744
-0.026
-2.56%
华盛通- 最 高1.07
- 今 开1.00
- 成交量 60.67万股
- 最 低 0.9602
- 昨 收 1.00
- 总市值 3570.78万
- 52周最高 1.6899
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.75
- 委 比 -88.18%
- 总股本 3664.59万
- 历史最高 16.74
- 量 比 1.88
- 振 幅 10.98%
- 历史最低 0.5306
- 每 手 1
- 风险率 0.17%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多RenovoRx Expands Reach with RenovoCath Approval
RenovoRx ( ($RNXT) ) has issued an announcement. RenovoRx reported its third-qu...
今天 05:54
RenovoRx Q3 EPS $(0.08), Inline, Sales $266.000K Miss $405.333K Estimate
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 20 percent increase over losses of $(0.10) per share from the same period last year. The company
今天 05:11
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th
RenovoRx, Inc. ("RenovoRx") (Nasdaq: RNXT), a life-sciences company, announced that CEO Shaun Bagai will present at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20, 2025. He will discuss the commercial progress of its FDA-cleared RenovoCath drug-delivery device and updates on its Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer (LAPC). The Company also launched a post-marketing ...
11-04 13:30
RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET
<p><p align="justify">MOUNTAIN VIEW, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc., a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath® drug-delivery device, announced it will host its third quarter 2025 financial results conference call on November 13, 2025, at 4:30 p.m. ET. The call will discuss recent developments in RenovoCath® commercialization, the Phase III TIGeR-PaC trial fo...
10-27 12:30
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – MIT and Harvard scientists recently created...
10-17 21:50
RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD
<p>RenovoRx, Inc. 宣布聘请著名介入肿瘤学家 Thierry de Baère 教授加入其科学顾问委员会。De Baère 教授在局部区域癌症治疗领域拥有丰富经验，其专长与 RenovoRx 的 TAMP™ 技术平台高度契合。TAMP 技术通过 RenovoCath 设备实现靶向药物递送，旨在优化肿瘤治疗效果并减少系统毒性。RenovoRx 正在推进 TAMP 技术的临床试验，并致力于将其应用于更多商业机会。</p>
10-09 12:30
RenovoRx Completes First Registry-Eligible Patient Procedure In PanTheR Post-Marketing Registry Study At University Of Vermont Cancer Center
First Registry-Eligible Patient Procedure Commenced at the University of Vermont Cancer CenterBaptist Health Miami Cancer Institute and University of Pittsburgh Medical Center Join the University of Vermont Cancer Center
09-25 20:32
RenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites
The first registry-eligible patient procedure in RenovoRx's PanTheR Post-Marketing Registry Study was completed at the University of Vermont Cancer Center. Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center have joined the study. The PanTheR registry aims to gather real-world safety and performance data of the FDA-cleared RenovoCath device for solid tumor patients. RenovoRx plans to expand patient enrollment and tre...
09-25 12:30
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th
RenovoRx CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16-17, discussing the company's commercialization of RenovoCath and its Phase III TIGeR-PaC clinical trial for pancreatic cancer treatment. Bagai will highlight the trial's progress and the Data Monitoring Committee's recommendation to continue the study following the second interim analysis. The presentation will also cover ...
09-11 12:30
